Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT…
News
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT…
CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 15,…
CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 15,…
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
Celyad Oncology announces receipt of Nasdaq delisting notice
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Celyad Oncology announces receipt of Nasdaq delisting notice
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Erasca Reports First Quarter 2023 Financial Results and Business Updates
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
Erasca Reports First Quarter 2023 Financial Results and Business Updates
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction…
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction…
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with…
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with…